Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
Public ClinicalTrials.gov record NCT03812029. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effects of EYP001a (Vonafexor) with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH
Study identification
- NCT ID
- NCT03812029
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 30, 2019 (Actual)
- Primary completion
- Jun 16, 2021 (Actual)
- Completion
- Jul 6, 2021 (Actual)
- Last update posted
- May 6, 2023
2019 – 2021
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ENYO PHARMA Investigative site 0424 | North Little Rock | Arkansas | 72117 | — |
| ENYO PHARMA Investigative site 0418 | Lakewood Rch | Florida | 34211 | — |
| ENYO PHARMA Investigative site 0402 | Ocoee | Florida | 34761 | — |
| ENYO PHARMA Investigative site 0420 | Orlando | Florida | 32806 | — |
| ENYO PHARMA Investigative site 0419 | Port Orange | Florida | 32127 | — |
| ENYO PHARMA Investigative site 0403 | Athens | Georgia | 30607 | — |
| ENYO PHARMA Investigative site 0423 | Savannah | Georgia | 31406 | — |
| ENYO PHARMA Investigative site 0407 | Snellville | Georgia | 30078 | — |
| ENYO PHARMA Investigative site 0409 | Indianapolis | Indiana | 46260 | — |
| ENYO PHARMA Investigative site 0413 | Baton Rouge | Louisiana | 70809 | — |
| ENYO PHARMA Investigative site 0404 | Marrero | Louisiana | 70072 | — |
| ENYO PHARMA Investigative site 0422 | Baltimore | Maryland | 21202 | — |
| ENYO PHARMA Investigative site 0412 | Jackson | Mississippi | 39216 | — |
| ENYO PHARMA Investigative site 0414 | Kansas City | Missouri | 64131 | — |
| ENYO PHARMA Investigative site 0406 | Durham | North Carolina | 27710 | — |
| ENYO PHARMA Investigative site 0411 | Columbus | Ohio | 43213 | — |
| ENYO PHARMA Investigative site 0401 | Charleston | South Carolina | 29401 | — |
| ENYO PHARMA Investigative site 0408 | Charleston | South Carolina | 29407 | — |
| ENYO PHARMA Investigative site 0421 | Rapid City | South Dakota | 57701 | — |
| ENYO PHARMA Investigative site 0405 | Arlington | Texas | 76012 | — |
| ENYO PHARMA Investigative site 0416 | Austin | Texas | 78746 | — |
| ENYO PHARMA Investigative site 0417 | Edinburg | Texas | 78539 | — |
| ENYO PHARMA Investigative site 0410 | San Antonio | Texas | 78215 | — |
| ENYO PHARMA Investigative site 0415 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03812029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2023 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03812029 live on ClinicalTrials.gov.